OSE Immunotherapeutics has been granted a patent for antibodies targeting human SIRPa, enhancing antigen presentation to T cells. The invention includes specific isoform antibodies disrupting SIRPa-CD47 interaction for disease treatment. A method for cancer treatment involving administering anti-SIRPa antibodies is also claimed. GlobalData’s report on OSE Immunotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights OSE Immunotherapeutics SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on OSE Immunotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. OSE Immunotherapeutics's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-human sirpa antibody for treating cancer

Source: United States Patent and Trademark Office (USPTO). Credit: OSE Immunotherapeutics SA

A recently granted patent (Publication Number: US11884723B2) outlines a method for treating cancer in subjects expressing SIRPa v1 by administering an anti-human SIRPa antibody or its fragments. The antibody enhances cross-presentation of antigens in the disease, eliciting a T cell response suitable for treatment. Specifically binding to human SIRPa v1, it inhibits the binding of human CD47 to SIRPa v1 without affecting SIRPg. The method targets various cancers, including inflammatory, metastatic, and melanoma, by enhancing antigen presentation and T cell response, potentially revolutionizing cancer treatment.

Moreover, the patent details the use of a pharmaceutical composition containing the anti-SIRPa antibody and a combination therapy with chemotherapeutic, immunotherapeutic, or radiotherapy agents to enhance immune responses. The method aims to activate T cells, enhance antigen presentation by dendritic cells, and polarize macrophages for effective cancer treatment. Additionally, the patent includes a method for assessing treatment effectiveness by detecting SIRPa v1 in biological samples, indicating the likelihood of cancer development. With a focus on breast, ovarian, and lung cancers, the patent offers a comprehensive approach to cancer treatment by leveraging the immune system's response to combat the disease effectively.

To know more about GlobalData’s detailed insights on OSE Immunotherapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies